New kidney disease collaboration for AZ, Evotec
AstraZeneca and Evotec have signed an agreement in the field of kidney diseases, with the initial focus being on exploring new treatments for chronic kidney disease.
Under the terms of the agreement, AstraZeneca will receive access to a selected series of molecules identified in a screening effort, which is part of Evotec’s systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca will provide industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec.
Dr Marcus Schindler, Head of Cardiovascular and Metabolic Diseases iMed, AstraZeneca.
While the upfront payment has not been disclosed, Evotec is eligible to pre-clinical, clinical and regulatory milestones, as well as additional milestones relating to commercialization.
Evotec, AstraZeneca Collaborate In Kidney Disease (London South East)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.